2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 330-333

  Argiriadi, Maria A ^a   Ericsson, Anna M ^a   Harris, Christopher M ^a   Banach, David L ^a   Borhani, David W ^a   Calderwood, David J ^a   Demers, Megan D ^a   DiMauro, Jennifer ^a   Dixon, Richard W ^a   Hardman, Jennifer ^a   Kwak, Silvia ^a   Li, Biqin ^a   Mankovich, John A ^a   Marcotte, Douglas ^a   Mullen, Kelly D ^a   Ni, Baofu ^a   Pietras, M ^a   Sadhukhan, Ramkrishna ^a   Sousa, Silvino ^a   Tomlinson, Medha J ^a   Wang, Lu ^a   Xiang, Tao ^a   Talanian, Robert V ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

Diaminopyrimidine; MAPKAP K2; MK2; TNF

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; DRUG BINDING; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ADENOSINE TRIPHOSPHATE; ANTI-INFLAMMATORY AGENTS; BINDING SITES; BINDING, COMPETITIVE; COMPUTER SIMULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 72049116018     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.102     Document Type: Article

References (26)

1. Goldstein D.M., and Gabriel T. Curr. Top. Med. Chem. 5 (2005) 1017
2. Feldmann M., Brennan F.M., Foxwell B.M., Taylor P.C., Williams R.O., and Maini R.N. J. Autoimmun. 25 (2005) 26
3. McInnes I.B., and Schett G. Nat. Rev. Immunol. 7 (2007) 429
4. Gaestel M., Kotlyarov A., and Kracht M. Nat. Rev. Drug Disc. 8 (2009) 480
5. Mbalaviele G., and Monahan J.B. Expert Opin. Drug Discovery 3 (2008) 163
6. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., and Gaestel M. Nat. Cell Biol. 1 (1999) 94
7. Hegen M., Gaestel M., Nickerson-Nutter C.L., Lin L.-L., and Telliez J.-B. J. Immunol. 177 (2006) 1913
8. Anderson D.R., Meyers M.J., Vernier W.F., Mahoney M.W., Kurumbail R.G., Caspers N., Poda G.I., Schindler J.F., Reitz D.B., and Mourey R.J. J. Med. Chem. 50 (2007) 2647
9. Mourey, R. J.; Anderson, G.; Hirsch, J.; Meyers, M.; Mnich, S.; Stillwell, L.; Thiede, M.; Vernier, W.; Webb, E.; Zhang, J.; Gaestel, M.; Monahan, J. In Pharmacological characterization of a small molecule inhibitor of MAPKAP kinase-2 (MK-2) for the inhibition of TNFα production; 14th International Conference of the Inflammation Research Association, Cambridge, MD, 2006.
10. Harris, C. M.; Ericsson, A. M.; Argiriadi, M. A.; Barberis, C.; Borhani, D. W.; Burchat, A.; Calderwood, D. J.; Cunha, G. A.; Dixon, R. W.; Frank, K. E.; Johnson, E. F.; Kamens, J.; Kwak, S.; Li, B.; Mullen, K. D.; Perron, D. C.; Wang, L.; Wishart, N.; Wu, X.; Zhang, X.; Zmetra, T. R.; Talanian, R. V. Bioorg. Med. Chem. Lett. (2009), doi:10.1016/jbmcl.2009.10.103.
11. To measure the effect of p38 activation, nonphosphorylated MK2 samples were assayed with and without 2 ng active p38α (upstate, no 14-251). Separate experiments demonstrated that p38α does not activate the MK2 assay peptide substrate (not shown).
12. Argiriadi M.A., Sousa S., Banach D., Marcotte D., Xiang T., Tomlinson M.J., Demers M., Harris C., Kwak S., Hardman J., Pietras M., Quinn L., DiMauro J., Ni B., Mankovich J., Borhani D.W., Talanian R.V., and Sadhukhan R. BMC Struct. Biol. 9 (2009) 16
13. Jia Y., Quinn C.M., Gagnon A., and Talanian R. Anal. Biochem. 356 (2006) 273
14. Ben-Levy R., Leighton I.A., Doza Y.N., Attwood P., Morrice N., Marshall C.J., and Cohen P. EMBO J. 14 (1995) 5920
15. Ben-Levy R., Hooper S., Wilson R., Paterson H.F., and Marshall C.J. Curr. Biol. 8 (1998) 1049
16. Engel K., Kotlyarov A., and Gaestel M. EMBO J. 17 (1998) 3363
17. Hubbard S.R., Wei L., Ellis L., and Hendrickson W.A. Nature 372 (1994) 746
18. Bosworth N., and Towers P. Nature 341 (1989) 167
19. Zheng J., Knighton D.R., ten Eyck L.F., Karlsson R., Xuong N., Taylor S.S., and Sowadski J.M. Biochemistry 32 (1993) 2154
20. Goldberg J., Nairn A.C., and Kuriyan J. Cell 84 (1996) 875
21. Underwood K.W., Parris K.D., Federico E., Mosyak L., Czerwinski R.M., Shane T., Taylor M., Svenson K., Liu Y., Hsiao C.L., Wolfrom S., Maguire M., Malakian K., Telliez J.B., Lin L.L., Kriz R.W., Seehra J., Somers W.S., and Stahl M.L. Structure 11 (2003) 627
22. Chu X.J., DePinto W., Bartkovitz D., So S.S., Vu B.T., Packman K., Lukacs C., Ding Q., Jiang N., Wang K., Goelzer P., Yin X., Smith M.A., Higgins B.X., Chen Y., Xiang Q., Moliterni J., Kaplan G., Graves B., Lovey A., and Fotouhi N. J. Med. Chem. 49 (2006) 6549
23. Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C., Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L., Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N., Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M., and Vajdos F. Cancer Res. 68 (2008) 1935
24. Baumli S., Lolli G., Lowe E.D., Troiani S., Rusconi L., Bullock A.N., Debreczeni J.E., Knapp S., and Johnson L.N. EMBO J. 27 (2008) 1907
25. free 29.7 and 26.5, respectively. The coordinates for the crystal structures of MK2/2 and MK2/3 are deposited in the Protein Data Bank with IDs 3KC3 and 3KA0, respectively. Full details of crystal data collection, structure determination and a table of structure statistics are in Supplementary data.
26. Meng W., Swenson L.L., Fitzgibbon M.J., Hayakawa K., ter Haar E., Behrens A.E., Fulghum J.R., and Lippke J.A. J. Biol. Chem. 277 (2002) 37401